axicabtagene ciloleucel
gilead,daiichi sankyo
['zuma-7', 'axi-cel', 'axicabtagene ciloleucel', 'lymphoma', 'axicel', 'crispr']
#ash22
abstract 659 - a ghobadi et al.
zuma-7 outcomes for patients who received subsequent cellular therapy appeared better when cellular therapy is given earlier (2l versus 3l) 3l car t-cell therapy after initial response to axi-cel in 2l appears to be a viable option 
Hematologist at Saint Antoine Hospital, Paris, France @Sorbonne_Univ_ @APHP. @JACIE_EBMT National Representative. #BMTsm #LYMsm #CARTcell #CardioOnc #QoL